

## Onconova Therapeutics Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 07-Feb-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

# Onconova Therapeutics Inc

## COMPANY OVERVIEW

|  |   |
|--|---|
| <b>Company Name</b>                          | Onconova Therapeutics Inc   |
| <b>Parent Company Name</b>                   | Onconova Therapeutics Inc   |
| <b>Website</b>                               | http://www.onconova.com/  |
| <b>Country</b>                               | US  |
| <b>Number of Drugs in Active Development</b> | 15  |
| <b>Number of Inactive Drugs</b>              | 7   |
| <b>Number of Patents as Owner</b>            | 14  |
| <b>Number of Patents as Third Party</b>      | 0   |
| <b>Number of Deals</b>                       | 15  |
| <b>Key Indications</b>                       | Cancer,Hematological neoplasm,Radiation sickness,Solid tumor,Myelodysplastic syndrome,Toxicity,Acute lymphoblastic leukemia,Acute myelogenous leukemia,Central nervous system disease,Inflammatory disease,Ovary tumor,Pancreas tumor   |
| <b>Key Target-based Actions</b>              | Abl tyrosine kinase inhibitor,Cyclin-dependent kinase-1 inhibitor,Cyclin-dependent kinase inhibitor 1 inhibitor,p53 tumor suppressor protein inhibitor,Bax protein inhibitor,Polo-like kinase 1 inhibitor,Tumor protein p73 inhibitor,AKT protein kinase inhibitor,BCL2L11 gene stimulator,Bcr protein inhibitor,Cyclin D1 inhibitor,Cyclooxygenase 2 inhibitor,Jun N terminal kinase modulator,MAP kinase inhibitor,Phosphoinositide 3-kinase inhibitor,Tubulin beta inhibitor |
| <b>Key Technologies</b>                      | Small molecule therapeutic,Oral formulation,Intravenous formulation,Infusion,Prodrug,Capsule formulation,Subcutaneous formulation,Formulation preservation,Solution,Analytical method,Cell targeting,Drug screening,Injectable formulation,Liquid   |

## COMPANY PROFILE

### SUMMARY

Onconova Therapeutics is a private development-stage biopharmaceutical company founded in 1998, by scientific founder Dr Premkumar Reddy, focused on the development of treatments for cancer and radiation injury.

### COMPANY LOCATION

Onconova is located in Newtown, PA and Lawrenceville, NJ.

### LICENSING AGREEMENTS

In May 2008, KINAXO Biotechnologies and Onconova Therapeutics agreed to collaborate on the development of novel small molecule therapeutics for cancer treatment and radiation protection.

### EARLY R&D

By November 2008, Onconova was investigating a series of immunoconjugate compounds suitable for use with monoclonal antibodies. At that time, the company was seeking to outlicence the program to biopharmaceutical companies.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


| Indication | Active | Inactive | Total |
|------------|--------|----------|-------|
| Neoplasm   | 12     | 7        | 19    |

[Return to Table of Contents](#)

|                           |   |   |   |
|---------------------------|---|---|---|
| Hematological disease     | 3 | 0 | 3 |
| Injury                    | 2 | 0 | 2 |
| Gynecology and obstetrics | 1 | 1 | 2 |
| Endocrine disease         | 1 | 1 | 2 |
| Neurological disease      | 1 | 0 | 1 |
| Genitourinary disease     | 1 | 0 | 1 |
| Toxicity and intoxication | 1 | 0 | 1 |
| Gastrointestinal disease  | 1 | 0 | 1 |
| Inflammatory disease      | 1 | 0 | 1 |

### Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 3 Clinical   | 1               |
| Phase 2 Clinical   | 1               |
| Phase 1 Clinical   | 3               |
| Discovery          | 7               |
| Suspended          | 3               |

[Return to Table of Contents](#)

|                         |   |
|-------------------------|---|
| No Development Reported | 7 |
|-------------------------|---|

## DEALS

| Deal Type                                    | Principal |          | Partner |          | Total |
|--|-----------|----------|---------|----------|-------|
|  | Active    | Inactive | Active  | Inactive |       |
| Drug - Discovery/Design                      | 0         | 0        | 2       | 0        | 2     |
| Drug - Funding                               | 2         | 0        | 0       | 0        | 2     |
| Drug - CRADA                                 | 2         | 0        | 0       | 0        | 2     |
| Drug - Early Research/Development            | 1         | 0        | 5       | 0        | 6     |
| Drug - Development/Commercialization License | 1         | 0        | 0       | 0        | 1     |
| Drug - Commercialization License             | 1         | 0        | 0       | 0        | 1     |
| Drug - Development Services                  | 0         | 0        | 1       | 0        | 1     |

## CLINICAL TRIALS

### Trials by Condition Studied

| Condition Studied         | Ongoing | All |
|---------------------------|---------|-----|
| Neoplasm                  | 9       | 21  |
| Hematological disease     | 4       | 4   |
| Gastrointestinal disease  | 1       | 2   |
| Immune disorder           | 1       | 1   |
| Endocrine disease         | 0       | 1   |
| Gynecology and obstetrics | 0       | 1   |
| Genitourinary disease     | 0       | 1   |

### Trials by Phase

| Phase   | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 2       | 2   |
| Phase 2 | 1       | 3   |
| Phase 1 | 6       | 17  |

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

[Return to Table of Contents](#)





**Phase 2 Clinical**

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

**Phase 1 Clinical**

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

**PATENTS \***

| Indication                | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Cardiovascular disease    | 5        | 0              | 5     |
| Endocrine disease         | 1        | 0              | 1     |
| Gastrointestinal disease  | 3        | 0              | 3     |
| Hematological disease     | 4        | 0              | 4     |
| Degeneration              | 1        | 0              | 1     |
| Immune disorder           | 6        | 0              | 6     |
| Musculoskeletal disease   | 5        | 0              | 5     |
| Neoplasm                  | 11       | 0              | 11    |
| Genetic disorder          | 1        | 0              | 1     |
| Metabolic disorder        | 3        | 0              | 3     |
| Neurological disease      | 5        | 0              | 5     |
| Infectious disease        | 2        | 0              | 2     |
| Injury                    | 3        | 0              | 3     |
| Toxicity and intoxication | 1        | 0              | 1     |
| Inflammatory disease      | 7        | 0              | 7     |
| Gynecology and obstetrics | 1        | 0              | 1     |
| Dermatological disease    | 1        | 0              | 1     |
| Ulcer                     | 1        | 0              | 1     |

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio   |
| <b>Key Synonyms</b>         | rigosertib, Novonex, Estybon, rigosertib sodium   |
| <b>Originator Company</b>   | Onconova Therapeutics Inc   |
| <b>Active Companies</b>     | Baxter International Inc, SymBio Pharmaceuticals Ltd, Onconova Therapeutics Inc   |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Phase 3 Clinical  |
| <b>Active Indications</b>   | Myelodysplastic syndrome, Hematological neoplasm, Acute myelogenous leukemia, Solid tumor, Pancreas tumor, Acute lymphoblastic leukemia, Ovary tumor  |
| <b>Target-based Actions</b> | Phosphoinositide 3-kinase inhibitor, MAP kinase inhibitor, AKT protein kinase inhibitor, Cyclin-dependent kinase-1 inhibitor, Jun N terminal kinase modulator, Polo-like kinase 1 inhibitor, BCL2L11 gene stimulator, Cyclin D1 inhibitor |
| <b>Other Actions</b>        | Apoptosis stimulator, Anticancer protein kinase inhibitor, Cell cycle inhibitor   |
| <b>Technologies</b>         | Intravenous formulation, Infusion, Small molecule therapeutic   |
| <b>Last Change Date</b>     | 19-Dec-2012   |

### rigosertib sodium (oral capsule, MDS/solid tumors), Onconova/SymBio

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | rigosertib sodium (oral capsule, MDS/solid tumors), Onconova/SymBio  |
| <b>Key Synonyms</b>         | Estybon, rigosertib sodium, Novonex, rigosertib  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc, SymBio Pharmaceuticals Ltd  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 2 Clinical   |
| <b>Active Indications</b>   | Myelodysplastic syndrome, Solid tumor  |
| <b>Target-based Actions</b> | Phosphoinositide 3-kinase inhibitor, MAP kinase inhibitor, AKT protein kinase inhibitor, Cyclin-dependent kinase-1 inhibitor, Jun N terminal kinase modulator, Polo-like kinase 1 inhibitor, BCL2L11 gene stimulator |
| <b>Other Actions</b>        | Cell cycle inhibitor, Anticancer protein kinase inhibitor, Apoptosis stimulator  |
| <b>Technologies</b>         | Oral formulation, Capsule formulation, Small molecule therapeutic  |
| <b>Last Change Date</b>     | 28-Dec-2012  |

[Return to Table of Contents](#)

### recilisib sodium (sc, radiation sickness), Onconova

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | recilisib sodium (sc, radiation sickness), Onconova  |
| <b>Key Synonyms</b>         | Ex-RAD, recilisib sodium, recilisib  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 1 Clinical   |
| <b>Active Indications</b>   | Radiation sickness   |
| <b>Target-based Actions</b> | Cyclin-dependent kinase inhibitor 1 inhibitor, p53 tumor suppressor protein inhibitor, Bax protein inhibitor, Tumor protein p73 inhibitor, Abl tyrosine kinase inhibitor |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor, Radioprotectant, Apoptosis inhibitor  |
| <b>Technologies</b>         | Subcutaneous formulation, Small molecule therapeutic   |
| <b>Last Change Date</b>     | 17-Oct-2012  |

### ON-013105

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-013105  |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 1 Clinical   |
| <b>Active Indications</b>   | Hematological neoplasm   |
| <b>Target-based Actions</b> | Cyclin D1 inhibitor  |
| <b>Other Actions</b>        | Apoptosis stimulator, Cell cycle inhibitor                             |
| <b>Technologies</b>         | Prodrug, Intravenous formulation, Infusion, Small molecule therapeutic |
| <b>Last Change Date</b>     | 02-Aug-2012  |

[Return to Table of Contents](#)



## recilisib sodium (oral, radiation sickness), Onconova

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | recilisib sodium (oral, radiation sickness), Onconova  |
| <b>Key Synonyms</b>         | Ex-RAD, recilisib, recilisib sodium  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 1 Clinical   |
| <b>Active Indications</b>   | Radiation sickness   |
| <b>Target-based Actions</b> | Cyclin-dependent kinase inhibitor 1 inhibitor, p53 tumor suppressor protein inhibitor, Bax protein inhibitor, Tumor protein p73 inhibitor, Abl tyrosine kinase inhibitor |
| <b>Other Actions</b>        | Radioprotectant, Anticancer protein kinase inhibitor, Apoptosis inhibitor  |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic   |
| <b>Last Change Date</b>     | 17-Oct-2012  |

## ON-24160

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-24160                                     |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                    |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                    |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery                                    |
| <b>Active Indications</b>   | Cancer                                       |
| <b>Target-based Actions</b> | Tubulin beta inhibitor                       |
| <b>Other Actions</b>        | Anticancer                                   |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 08-Jun-2012                                  |

[Return to Table of Contents](#)

**ON-044580**

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | ON-044580   |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Onconova Therapeutics Inc   |
| <b>Active Companies</b>     | Onconova Therapeutics Inc   |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | Cancer  |
| <b>Target-based Actions</b> | Bcr protein inhibitor, IL-3 antagonist, Abl tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, STAT-5 inhibitor |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor, Apoptosis stimulator   |
| <b>Technologies</b>         | Small molecule therapeutic  |
| <b>Last Change Date</b>     | 11-Jun-2012   |

**ON-123300**

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-123300  |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Cancer   |
| <b>Target-based Actions</b> | NUAK SNF1-like protein kinase 1 inhibitor, Cyclin-dependent kinase-4 inhibitor |
| <b>Other Actions</b>        | Apoptosis stimulator, Anticancer protein kinase inhibitor                      |
| <b>Technologies</b>         | Small molecule therapeutic   |
| <b>Last Change Date</b>     | 11-Jun-2012  |

[Return to Table of Contents](#)

**ON-1231320**

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | ON-1231320                                    |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                     |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                     |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery                                     |
| <b>Active Indications</b>   | Cancer  |
| <b>Target-based Actions</b> | Polo-like kinase 2 inhibitor, PARP stimulator |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor           |
| <b>Technologies</b>         | Small molecule therapeutic                    |
| <b>Last Change Date</b>     | 08-Jun-2012                                   |

**ALK inhibitors (cancer), Onconova**

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | ALK inhibitors (cancer), Onconova             |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                     |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                     |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery                                     |
| <b>Active Indications</b>   | Cancer  |
| <b>Target-based Actions</b> | Anaplastic lymphoma kinase receptor inhibitor |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor           |
| <b>Technologies</b>         | Small molecule therapeutic                    |
| <b>Last Change Date</b>     | 26-Sep-2012                                   |

[Return to Table of Contents](#)

**ON-108600**

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | ON-108600   |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                                       |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                                       |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | Cancer  |
| <b>Target-based Actions</b> | Casein kinase II inhibitor, Cyclin-dependent kinase-9 inhibitor |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor, Cell cycle inhibitor       |
| <b>Technologies</b>         | Small molecule therapeutic                                      |
| <b>Last Change Date</b>     | 19-Jun-2012   |

**PI3K alpha and delta isoform inhibitors (hematological malignancies), Onconova**

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | PI3K alpha and delta isoform inhibitors (hematological malignancies), Onconova       |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Hematological neoplasm   |
| <b>Target-based Actions</b> | Phosphoinositide-3 kinase alpha inhibitor, Phosphoinositide-3 kinase delta inhibitor |
| <b>Other Actions</b>        | Anticancer   |
| <b>Technologies</b>         | Small molecule therapeutic   |
| <b>Last Change Date</b>     | 24-Nov-2012  |

[Return to Table of Contents](#)


**ON-09300**

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-09300   |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                            |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                            |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Cancer   |
| <b>Target-based Actions</b> | Cyclooxygenase 2 inhibitor, 5-Lipoxygenase inhibitor |
| <b>Other Actions</b>        | Anticancer   |
| <b>Technologies</b>         | Small molecule therapeutic                           |
| <b>Last Change Date</b>     | 14-Nov-2008  |

**ON-09250**

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-09250   |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc                            |
| <b>Active Companies</b>     | Onconova Therapeutics Inc                            |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Central nervous system disease, Inflammatory disease |
| <b>Target-based Actions</b> | Cyclooxygenase 2 inhibitor                           |
| <b>Other Actions</b>        | Anti-inflammatory                                    |
| <b>Technologies</b>         | Small molecule therapeutic                           |
| <b>Last Change Date</b>     | 09-Aug-2004  |

[Return to Table of Contents](#)



### ON-01500 series, Onconova

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ON-01500 series, Onconova  |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Onconova Therapeutics Inc  |
| <b>Active Companies</b>     | Onconova Therapeutics Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Toxicity, Cancer   |
| <b>Target-based Actions</b> | Cyclin-dependent kinase-1 inhibitor  |
| <b>Other Actions</b>        | Anticancer, Chemoprotectant, Cell cycle inhibitor, Anticancer protein kinase inhibitor, Angiogenesis inhibitor |
| <b>Technologies</b>         | Small molecule therapeutic   |
| <b>Last Change Date</b>     | 02-Jun-2010  |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)